Phase III international randomized trial | PRODIGE/CCTG Investigators | n = 493 | Resected PDAC | New England Journal of Medicine 2018 **Conroy et al.** Thierry Conroy Published in New England Journal of Medicine, 2018 Enrollment: 2012–2016 [PubMed Link](https://pubmed.ncbi.nlm.nih.gov/30575490/) --- ### Essential Takeaway PRODIGE-24 demonstrated dramatic improvements in disease-free and overall survival with adjuvant modified FOLFIRINOX compared with gemcitabine alone after PDAC resection. The trial established mFOLFIRINOX as the modern adjuvant standard for fit patients and became one of the most practice-changing studies in pancreatic cancer. --- ### Clinical Question Does adjuvant modified FOLFIRINOX improve survival compared with gemcitabine alone after curative-intent resection of pancreatic ductal adenocarcinoma? --- ### Population - Resected PDAC - R0 or R1 resections - ECOG 0–1 - CA19-9 <180 U/mL - Adequate postoperative recovery Patients were highly selected and generally fit for intensive multi-agent chemotherapy. --- ### Study Design #### Arm 1 — Gemcitabine Alone - Gemcitabine - 6 months total therapy #### Arm 2 — Modified FOLFIRINOX Modified regimen included: - oxaliplatin - irinotecan - leucovorin - infusional 5-FU Modifications: - no bolus 5-FU - reduced irinotecan dose Treatment duration: - 12 cycles - 6 months total --- ### Endpoints #### Primary Endpoint Disease-free survival (DFS) #### Secondary Endpoints - Overall survival (OS) - Metastasis-free survival - Cancer-specific survival - Safety/toxicity - Quality of life --- ### Key Results #### Disease-Free Survival Major improvement with mFOLFIRINOX: - 21.6 vs 12.8 months - HR 0.58 - p < 0.001 --- #### Overall Survival Substantial OS improvement: - 54.4 vs 35.0 months - HR 0.64 - p < 0.001 This represented one of the largest survival gains ever demonstrated in resected PDAC. --- #### Metastasis-Free Survival - 30.4 vs 17.7 months Supported the importance of systemic disease control in pancreatic cancer. --- ### Toxicity mFOLFIRINOX increased: - neutropenia - diarrhea - fatigue - sensory neuropathy Grade 3–4 adverse events: - 75.9% vs 52.9% Despite increased toxicity, treatment completion remained feasible in selected fit patients. --- ### Additional Findings #### Redefined Expectations for Survival Median OS exceeding 4 years represented a major shift in achievable outcomes after PDAC resection. #### Reinforced PDAC as a Systemic Disease The magnitude of metastasis-free survival benefit emphasized the importance of aggressive systemic therapy even after apparently curative surgery. --- ### Interpretation PRODIGE-24 became one of the most influential trials in pancreatic oncology because it dramatically improved both DFS and OS compared with prior adjuvant standards. The study firmly established intensified multi-agent systemic therapy as superior to gemcitabine monotherapy and fundamentally changed postoperative management of fit PDAC patients. It also accelerated broader movement toward: - treatment intensification - systemic-first thinking - perioperative therapeutic strategies throughout pancreatic cancer care. --- ### Important Limitations #### Highly Selected Population Patients were: - younger - fitter - lower CA19-9 burden - better postoperative recovery than many real-world PDAC populations. #### Significant Toxicity Treatment-related toxicity was substantial and limits applicability in frailer patients. #### Surgery-First Era The trial preceded widespread adoption of neoadjuvant therapy and total neoadjuvant paradigms. #### Applicability Results apply primarily to: - fit postoperative patients - ECOG 0–1 populations - adequate postoperative recovery --- ### Practice Impact PRODIGE-24 established modified FOLFIRINOX as the preferred adjuvant regimen for medically fit patients after PDAC resection. The trial fundamentally changed modern pancreatic cancer management by demonstrating that substantial long-term survival improvement was achievable with intensified systemic therapy. PRODIGE-24 rapidly supplanted: - gemcitabine monotherapy - gemcitabine/capecitabine as the dominant adjuvant standard in eligible patients and remains one of the most practice-changing trials in PDAC history.